Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report

BACKGROUND: Epidermal growth factor receptor (EGFR)-mutant nonsmall cell lung cancer (NSCLC) patients are less likely to be programmed death-ligand 1 (PD-L1)-positive compared with wild-type EGFR mutant tumors. Given the rarity of actionable driver genes in squamous cell lung cancer (SQCC), the freq...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiu-Xia, Wei, Jian-Guo, Chen, Yi-Yi, Wang, Jian-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387979/
https://www.ncbi.nlm.nih.gov/pubmed/35984168
http://dx.doi.org/10.1097/MD.0000000000030099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387979/
https://www.ncbi.nlm.nih.gov/pubmed/35984168
http://dx.doi.org/10.1097/MD.0000000000030099

Ejemplares similares